Ethics Management
- Compliance Program(CP)
- CEO Declaration of Voluntary Compliance
- Anti-Corruption Policy
- CP Operation
- Whistleblowing system
- Organization Chart
What is Compliance program (CP)?
It refers an internal compliance system established by companies to comply with fair trade-related laws, including training and supervision.
< 7 Elements of the CP >
CEO Declaration of Voluntary Compliance
As all members of the BC family put honesty, consideration, and cooperation as our top priorities, we practice people-oriented, top-oriented, and customer satisfaction throughout the company, and are entering the global market based on overseas patents.
In order to impress our customers and to leap forward as a global pharmaceutical company, we need to develop centered on ethical management and compliance management.
As part of that commitment, we declare the introduction of the Compliance Program.
Compliance program is a system that can improve the voluntary compliance awareness of our employees by suggesting specific behavioral standards for compliance with fair trade-related laws and prevent risks of violations of the law in advance.
We must serve as a good model in the pharmaceutical industry, where there is a high risk of violating the law.
In this regard, representative behavioral guidelines are as follows. We ask for your actions.
First, we do not provide excessive profits to customers or compete unfairly.
Second, we comply with the Fair Competition Codes approved by the Fair Trade Commission.
Third, we do not reduce the price or cancel the consignment contrary to the contents of the contract with the partner.
Any employee who violates the Code of Conduct or violates fair trade laws will be subject to HR penalties and strictly held accountable.
Please keep in mind that we will not tolerate any violations of the law regardless of the interests and interests of our employees.
In order to impress our customers and to leap forward as a global pharmaceutical company, we need to develop centered on ethical management and compliance management.
As part of that commitment, we declare the introduction of the Compliance Program.
Compliance program is a system that can improve the voluntary compliance awareness of our employees by suggesting specific behavioral standards for compliance with fair trade-related laws and prevent risks of violations of the law in advance.
We must serve as a good model in the pharmaceutical industry, where there is a high risk of violating the law.
In this regard, representative behavioral guidelines are as follows. We ask for your actions.
First, we do not provide excessive profits to customers or compete unfairly.
Second, we comply with the Fair Competition Codes approved by the Fair Trade Commission.
Third, we do not reduce the price or cancel the consignment contrary to the contents of the contract with the partner.
Any employee who violates the Code of Conduct or violates fair trade laws will be subject to HR penalties and strictly held accountable.
Please keep in mind that we will not tolerate any violations of the law regardless of the interests and interests of our employees.
September 1st, 2014
Anti-Corruption Policy
BC WORLD PHARMACEUTICAL and all employees are to share the right corporate view and practice ethic management.
Accordingly, we pledge to enact and uphold anti-corruption policies to strengthen sustainable growth and corporate social responsibility
and ethical management as a respected global healthcare company based on the company's management philosophy.
- Article 1 (Purpose)
- The purpose of this policy is to establish an anti-corruption management system by setting the behavioral standards of executives and employees of BC WORLD PHARMACEUTICAL for the prevention of corruption.
- Article 2 (Anti-corruption and bribery)
- Under no circumstances shall we accept, offer, or engage in conflicts of interest with bribes such as money, entertainment, or convenience from/to relevant stakeholders.
- Article 3 (Compliance with anti-corruption and anti-bribery regulations)
- In carrying out our business, we comply with all anti-corruption laws including the Republic of Korea's 「Criminal Act」, 「Act On The Aggravated Punishment Of Specific Crimes」, 「Act On Combating Bribery Of Foreign Public Officials In International Business Transactions」, and 「Improper Solicitation And Graft Act」, overseas anti-corruptions laws such as the 「Foreign Corrupt Practices Act」 of the United States, and the 「Bribery Act」 of the United Kingdom, and internal regulations and do not engage in suspicious activity that are violated or suspected of being violated.
- Article 4 (Suitable for organizational purposes)
- We comply with the company's anti-corruption policy and anti-corruption management system to eliminate the risk of corruption and bribery, thereby contributing to ethical management for the company's sustainable growth.
- Article 5 (Commitment to implementation and improvement of anti-corruption and bribery)
- To prevent and control the risk of corruption and bribery, we establish and operate an effective anti-corruption management system, and continuously improve it to disseminate it to all stakeholders. In addition, all executives and employees sign and fulfill the pledge of anti-corruption at least once a year.
- Article 6 (Authority and Responsibilities of the Anti-Corruption Officer)
- The anti-corruption officer designated for the company's anti-corruption is given independent responsibility and authority related to anti-corruption and bribery, and continuously improves the anti-corruption management system by establishing and implementing the company's anti-corruption goals.
- Article 7 (Protecting the identity of whistleblowers of corruption and bribery)
- The company keeps the informant’s personal information of corruption and bribery strictly confidential, and, if the informant is a company’s employee, protects it from being evaluated, assigned, and economically unfavorable based on the report. The contribution of the informant to the company by reporting bribery is reflected in performance evaluations.
- Article 8 (Action in case of non-compliance with anti-corruption policy)
- If an employee violates this policy, the company will take appropriate steps in accordance with internal regulations.
- Appendix
- This regulation is enacted and enforced from July 1, 2019.
CP Operation
| Date | Contents |
|---|---|
| 2020-06-01 | ISO 37001 anti-corruption system awareness training and anti-corruption system guidance (training for company-wide team) |
| 2020-01-02 | 20-year Sales Department Voluntary Compliance Program (CP) Training |
| 2019-11-22 | ISO 37001 anti-corruption system certification (by KCCA) |
| 2019-07-01 | BCWP Anti-Corruption Policy enactment and employee pledge |
| 2019-05-02 | BCWP Code of Ethics enactment, education, and pledge |
| 2019-04-08 | BCWP CP guideline renewal and training for sales division |
| 2019-03-11 | BCWP CP dedicated department established |
| 2019-03-01 | Established CP Economic Profit Expenditure Report 2018 |
| 2017-09-19 | Education on the Understanding of Compliance program (CP) and detailed operating standards – Relevant departments (Sales Department, Financial Management Team, Human Resources Team, Development Team, External Cooperation Team, and Clinical Research Planning Team) |
| 2017-09-06 | Education on the understanding and operation of the Compliance Program (CP) - Sales meeting in September |
| 2017-08-21 | Training for August New employee on compliance program (CP) |
| 2017-08-09 | Education on the understanding and operation of the Compliance Program (CP) - Sales meeting in August |
| 2017-07-07 | Education on the understanding and operation of the Compliance Program (CP) - Group training for the sales division in the second half of the year |
| 2017-06-05 | Education on amendments to the Fair Competition Code and detailed operating standards regarding drug trade - Sales meeting |
| 2017-06-01 | Amendment and application of expenditure report form according to partial amendments to the Enforcement Rules of the Pharmaceutical Affairs Act |
| 2017-03-13 | Reorganization of Compliance Organization |
| 2017-02-27 | Training for the Experienced Employees on Compliance Program (CP) |
| 2017-01-06 | Training on the understanding and operation of the Compliance Program (CP) - Group training at the opening ceremony |
| 2016-12-05 | Training for December New employee on compliance program (CP) |
| 2016-10-04 | Training for the employees of open recruitment in the second half of the year, on compliance program (CP) |
| 2016-09 | Branch Tour Training on Anti-Corruption and Graft Act + Compliance Program (CP) |
| 2016-07-08 | Training for the sales-related departments (sales department, sales management, development, marketing, finance) on CP - group training |
| 2016-05-23 | Training for the employees of open recruitment in the first half of the year, on compliance program (CP) |
| 2015-12-08 | Training for the employees of December on compliance program (CP) |
| 2015-10-14 | Training for the employees of open recruitment in the second half of the year, on compliance program (CP) |
| 2015-07-20 | Training for the experienced employees on Compliance Program (CP) |
| 2015-07-03 | Training on the understanding and operation of the CP program - Group training for the sales division |
| 2015-04-13 | Training for the employees of open recruitment in the first half of the year, on compliance program (CP) |
| 2015-01-09 | Training on the understanding and operation of the Compliance Program (CP) - Group training at the opening ceremony |
| 2014-10-23 | Consultation with the Fair Trade Lawyer of Fair Competition Federation |
| 2014-10-10 | Preparation and review of feasibility auditors related to fair trade work (all departments) |
| 2014-10-07 | Training on the understanding and operation of the Compliance Program (CP) - Sales Meeting |
| 2014-10-05 | Education on Fair Trade Association Fair Trade Lawyer Consultation - Sales Meeting |
| 2014-10-01 | Test on CP training (all employees) |
- Whistleblowing system
- · Unfair joint actions by stakeholders, such as bid rigging for the purpose of doing business with the company
- · Acts deviating from the Code of Conduct for Fair Subcontract Transactions
- · Unfair trade practices such as other abuse of position in trade (refer to the Code of Conduct in the Compliance Program Manual)
- · Disadvantageous treatment and exposure of identity against the legitimate reporters
- · Unfair trade practices such as other abuse of position in trade including fair trade act, fair labelling act, electronic transactions act, act on the regulation of terms and conditions (refer to the Code of Conduct in the Compliance Program Manual)
- · Report corruption and unfair trade practices of business partners
- · Acts of acceptance of unreasonable money, goods, entertainment, or convenience from stakeholders
- · A person who took part in a case of bribery or embezzlement
- · Acts of obtaining unfair benefits or damaging the company by using the position or duties
- · Acts of interfering with the fair business of other employees for the benefit of themselves or others
- · Acts of leaking corporate secrets and customer information without permission
- Protection of reporter
- · Strictly guarantee the confidentiality of the identity of the reporter and the contents of the report
- · Prohibition of divulging the identity of the reporter and finding the reporter (punishing the violators)
- · Prohibition of discrimination and disadvantageous treatment against the reporter (punishing the violators)
- Report Desk (Compliance Program Officer)
- Compliance Program Officer Name (Title) : Ha Yong-jeong ㅣ Telephone : +82-31-5178-0380 ㅣ E-mail : bcwpCP@bcwp.co.kr
- ※ Within 3 days of reporting, the compliance program officer will notify the reporter of the case processing status or results directly or in writing (including e-mail).
Organization Chart
